Cipla Ltd

Cipla Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Cipla Ltd

₹ 1,256 1.39%
20 Mar - close price
cipla.com BSE: 500087 NSE: CIPLA
About

Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs[1]

Key Points

Market Leadership[1]
# 3rd largest in the India domestic Rx market
# Leadership in Gx
# 1st rank in Respiratory
# Top 5 in Urology and Anti-infectives.
# Over 5 Lac+ no of downloads - Digital Breathe free
# 7,500+ field force detailing to HCPs across the country – 85% of physicians prescribe at least one Cipla product.
# 3rd largest player in private Rx market in SAGA
# Fastest growing generic player in North America.

Website BSE NSE
  • Market Cap ₹ 1,01,490 Cr.
  • Current Price ₹ 1,256
  • High / Low ₹ 1,673 / 1,235
  • Stock P/E 22.2
  • Book Value ₹ 412
  • Dividend Yield 1.03 %
  • ROCE 20.1 %
  • ROE 16.0 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 26.0%

Cons

  • The company has delivered a poor sales growth of 8.51% over past five years.
  • Promoter holding has decreased over last 3 years: -4.40%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of Nifty 50 BSE 500 BSE Healthcare BSE 100 BSE 200

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
3,536 3,566 4,318 4,234 4,381 4,037 4,501 4,775 4,971 4,798 5,046 5,226 4,498
2,707 2,854 3,114 3,009 3,025 3,209 3,141 3,337 3,309 3,479 3,422 3,703 3,777
Operating Profit 829 711 1,205 1,225 1,356 828 1,360 1,438 1,662 1,319 1,624 1,523 721
OPM % 23% 20% 28% 29% 31% 21% 30% 30% 33% 27% 32% 29% 16%
208 -1 158 319 265 595 214 289 189 588 271 255 172
Interest 6 9 0 7 9 5 5 3 4 3 6 3 4
Depreciation 130 162 136 180 135 137 138 146 143 148 146 141 153
Profit before tax 901 540 1,226 1,358 1,477 1,281 1,430 1,578 1,704 1,756 1,744 1,633 736
Tax % 25% 34% 27% 24% 25% 19% 26% 25% 16% 15% 25% 26% 16%
679 355 895 1,030 1,114 1,038 1,056 1,178 1,438 1,485 1,303 1,211 617
EPS in Rs 8.41 4.40 11.09 12.75 13.80 12.86 13.08 14.59 17.81 18.39 16.13 14.99 7.64
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
9,457 10,132 12,118 10,768 11,390 12,374 12,659 11,303 15,381 14,345 16,574 19,045 19,568
7,460 8,162 10,064 9,155 9,194 9,869 9,952 8,235 11,670 10,992 12,090 13,266 14,381
Operating Profit 1,996 1,969 2,053 1,613 2,196 2,505 2,707 3,067 3,711 3,353 4,484 5,778 5,187
OPM % 21% 19% 17% 15% 19% 20% 21% 27% 24% 23% 27% 30% 27%
273 140 280 113 257 575 893 654 742 640 1,434 1,279 1,286
Interest 128 136 147 39 12 17 36 45 27 22 20 15 16
Depreciation 324 433 443 500 530 570 600 469 547 596 588 574 588
Profit before tax 1,818 1,540 1,744 1,187 1,911 2,493 2,964 3,208 3,880 3,375 5,310 6,469 5,869
Tax % 24% 23% 16% 18% 23% 24% 22% 23% 24% 26% 23% 20%
1,388 1,181 1,462 975 1,469 1,888 2,318 2,468 2,958 2,513 4,077 5,158 4,616
EPS in Rs 17.29 14.71 18.20 12.12 18.24 23.44 28.75 30.61 36.66 31.14 50.50 63.86 57.15
Dividend Payout % 12% 14% 11% 16% 16% 13% 14% 16% 14% 27% 26% 25%
Compounded Sales Growth
10 Years: 7%
5 Years: 9%
3 Years: 7%
TTM: 7%
Compounded Profit Growth
10 Years: 15%
5 Years: 17%
3 Years: 18%
TTM: -2%
Stock Price CAGR
10 Years: 9%
5 Years: 10%
3 Years: 13%
1 Year: -18%
Return on Equity
10 Years: 13%
5 Years: 14%
3 Years: 14%
Last Year: 16%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 161 161 161 161 161 161 161 161 161 161 161 162 162
Reserves 9,931 10,930 11,825 12,640 13,952 15,621 17,242 19,766 22,352 24,477 27,812 31,938 33,083
877 1,381 1,132 324 174 0 6 52 23 50 46 117 125
1,955 2,721 2,121 2,482 2,807 2,637 2,997 2,984 2,912 2,908 3,034 3,349 4,075
Total Liabilities 12,924 15,192 15,239 15,607 17,095 18,419 20,406 22,964 25,449 27,596 31,053 35,566 37,445
3,524 3,594 3,826 4,236 4,320 4,189 4,151 4,066 3,910 3,809 3,719 3,878 4,268
CWIP 377 361 551 556 463 297 320 355 268 504 670 638 581
Investments 3,587 4,421 4,256 4,286 4,637 5,815 7,190 9,726 10,974 11,909 13,794 17,351 17,474
5,436 6,816 6,606 6,530 7,675 8,117 8,745 8,816 10,298 11,374 12,871 13,699 15,121
Total Assets 12,924 15,192 15,239 15,607 17,095 18,419 20,406 22,964 25,449 27,596 31,053 35,566 37,445

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
1,812 1,051 1,728 2,207 1,117 1,468 2,018 3,460 2,773 3,035 3,727 3,301
-1,467 -1,194 -1,206 -1,192 -593 -1,148 -1,127 -3,361 -2,464 -2,758 -2,883 -2,309
-404 180 -547 -1,011 -351 -473 -694 -66 -427 -425 -709 -1,074
Net Cash Flow -59 37 -25 5 173 -153 197 33 -117 -148 135 -82

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 67 74 57 66 75 93 103 98 66 73 59 74
Inventory Days 244 302 217 234 267 232 255 274 215 242 234 241
Days Payable 93 126 74 114 139 120 136 133 97 121 121 126
Cash Conversion Cycle 217 250 201 185 203 206 222 239 184 195 172 189
Working Capital Days 92 91 88 105 126 145 146 149 124 176 160 154
ROCE % 19% 14% 14% 9% 14% 16% 17% 15% 18% 13% 19% 20%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
R&D Spend as % of Revenue
%

Log in to view insights

Please log in to see hidden values.

Login
Number of Brands with revenue > INR 100 Crore in India
Count
Brands in Top 300 of IPM
Count
Cumulative ANDAs/NDAs Filed (US)
Count
India Pharmaceutical Market (IPM) Market Share
%
Manufacturing Facilities
Count
South Africa Private Market Share
%
R&D Expenditure (Percentage of Turnover)
%

Shareholding Pattern

Numbers in percentages

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
33.55% 33.46% 33.46% 33.46% 33.46% 30.91% 30.93% 29.19% 29.20% 29.19% 29.22% 29.22%
27.42% 25.49% 25.74% 25.73% 25.82% 27.82% 28.80% 26.65% 26.28% 25.24% 24.54% 23.93%
21.83% 24.05% 23.90% 24.05% 24.15% 24.66% 23.95% 27.49% 27.89% 28.98% 29.98% 30.45%
0.21% 0.21% 0.21% 0.21% 0.21% 0.21% 0.21% 0.23% 0.26% 0.27% 0.27% 0.27%
16.99% 16.76% 16.68% 16.53% 16.36% 16.40% 16.11% 16.43% 16.36% 16.30% 15.99% 16.12%
No. of Shareholders 4,75,2934,66,5154,26,8634,25,7314,36,1544,63,5694,70,2345,25,1145,43,4205,49,6555,34,5875,40,521

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls